Trial Profile

A Nonrandomized, Open-label, Multicenter, Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Subjects with Advanced Solid Tumors and Hematologic Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Jun 2025 Preliminary results (N=13) from the dose-escalation stage of a phase I trial presented in InnoCare Pharma media release.
01 Jun 2025 According to a InnoCare Pharma media release, data from this study were presented in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
26 Mar 2025 According to a Keymed Biosciences media release, preliminary results demonstrated a favorable PK profile with sufficient exposure for target coverage and regulatory T-cell depletion.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com